Advanced Search
CHENG-Bo, ZHANG Ai-min, MA Fu-jun, LI Shu-guang, HU Hai-long, LIU Li-wei, HAN Ru-fa. Diagnosis and Treatment of Renal Pelvis Carcinoma (Report of 92 Cases)[J]. Cancer Research on Prevention and Treatment, 2011, 38(08): 933-936. DOI: 10.3971/j.issn.1000-8578.2011.08.020
Citation: CHENG-Bo, ZHANG Ai-min, MA Fu-jun, LI Shu-guang, HU Hai-long, LIU Li-wei, HAN Ru-fa. Diagnosis and Treatment of Renal Pelvis Carcinoma (Report of 92 Cases)[J]. Cancer Research on Prevention and Treatment, 2011, 38(08): 933-936. DOI: 10.3971/j.issn.1000-8578.2011.08.020

Diagnosis and Treatment of Renal Pelvis Carcinoma (Report of 92 Cases)

More Information
  • Received Date: August 08, 2010
  • Revised Date: April 28, 2011
  • ObjectiveTo discuss the diagnostic and therapeutic methods of renal pelvic carcinoma. MethodsWe retrospectively analyzed the clinical and follow-up data of 92 patients with renal pelvic carcinoma.52 cases were male.Mean age was 64 years ranged from 41 to 82 years. Carcinoma was located at left in 49 cases and right in 43 cases.All patients were treated surgically. 73 cases were open nephroureterectomy with bladder cuff excision (20 cases of T1~2,group A), and 19 cases were nephroureterectomy with of bladder cuff excision using retroperitoneal laparoscopy plus transurethral resection (19 cases of T1~2,group B). ResultsOne time positive of the urine cytology was 68 cases (73.9%),and three times positive was 29 cases (31.5%). Ratios of final diagnosis of renal pelvic carcinoma by intravenous pyelogram (IVU),B ultrasound and computed tomography (CT) were 38.6%(32/83), 78.4%(69/88)and 84.6%(66/78),respectively.The pathological type of 82 cases was transitional cell carcinoma,and of 10 cases was squamous cell carcinoma with transitional cell carcinoma.According to WHO grade, 15 cases was grade Ⅰ,56 cases was grade Ⅱ and 21 cases was gradeⅢ.TNM clinical stages were 55 cases with stage Ⅰ,7 cases with stage Ⅱ 22 cases withstage Ⅲ and8 cases with stageⅣ.100% cases were followed up and mean follow-up time was 38.5 months, ranged from 3 to 60 months.The 3-year and 5-year survival rates of stage Ⅰ~Ⅱ cases were 77.4% and 54.8%,respectively and significantly higher than those of stage Ⅲ~Ⅳ cases (26.7% and 13.3%,respectively), P<0.05.In group B,blood loss during operation,postoperative drainage, intestinal function,recovery after operation,hospital stay,transfusion and use of anodyne were significantly reduced than those in group A (P<0.05),while the tumor size and operating time were no significantly different (P>0.05) between two groups. ConclusionsHematuria was the most common symptom of renal pelvic carcinoma.Urine cytology,IVU and B ultrasound should be used as a routine examination for renal pelvic carcinoma. Retrograde pyelography or CT might be a useful adjuvant examination when IVU showed negative results.Early diagnosis and treatment of renal pelvic carcinoma were critical for long-term survival.Nephroureterectomy with bladder cuff excision was the preferred treatment,although retroperitoneal laparoscopy plus transurethral resection afforded an improved postoperative course with minimal invasion,fast recovery . The effective cancer control for patient with Ⅰ~Ⅱ stage tumor was similar between 2 surgical methods.
  • Related Articles

    [1]CHENG Jianping, ZHAO Xiaolin, LI Zhen, YANG Mengyuan, CAO Shichang, YU Jiufei. Clinical Observation of mXELIRI and mFOLFIRI Combined with Cetuximab in First-line Treatment of Metastatic Left-side Colon Cancer[J]. Cancer Research on Prevention and Treatment, 2020, 47(7): 542-546. DOI: 10.3971/j.issn.1000-8578.2020.19.1475
    [2]XU Qi, LIU Bixia, GU Linhui, ZHANG Shuangshuang, ZHOU Weimin, WU Xiaodan, YING Jieer, FENG Jianguo. Effects of Different Doses of Bevacizumab on Irinotecan Distribution in Nude Mice Bearing Human Colon Cancer Cell Xenografts[J]. Cancer Research on Prevention and Treatment, 2016, 43(4): 263-266. DOI: 10.3971/j.issn.1000-8578.2016.04.005
    [3]WANG Junbin, WU Qiong, ZOU Weiyan, WANG Zishu, YANG Yan, ZHENG Rongsheng. Therapeutic Effect of Raltitrexed or Fluorouracil plus Irinotecan as Second-line Treatment for Advanced Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2014, 41(12): 1335-1338. DOI: 10.3971/j.issn.1000-8578.2014.12.018
    [4]CUI Yongxia, LUO Zhifen, LU Chuangxin, ZHOU Jianwei, MA Ning, ZHOU Yun. Clinical Observation of Irinotecan Combined with Tegafur or 5-Fluorouracil as Second-Line Chemotherapy for Advanced Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2014, 41(07): 808-810. DOI: 10.3971/j.issn.1000-8578.2014.07.026
    [5]ZHAO Rongrong, WANG Yuanfang, LIU Bo, HAN Shumei, NIU Zuoxing. Clinical Study of Irinotecan Plus Cisplatin for Patients with Carcinoma of Unknown Primary Site[J]. Cancer Research on Prevention and Treatment, 2013, 40(10): 984-987. DOI: 10.3971/j.issn.1000-8578.2013.10.017
    [6]Zhang Huiqing, He Bo, Lu San, Wan Yiye. Second-line Chemotherapy with Irinotecan Plus Cisplatin for Patients with Advanced Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2012, 39(11): 1373-1375. DOI: 10.3971/j.issn.1000-8578.2012.11.023
    [7]LI Rong, LIU Xiu-feng, HE Ze-ming, HUA Hai-qing, WANG Lin, CHEN Ying-xia. Preliminary Clinical Observation on Irinotecan Combined with Continuous Infusion of Tegafur in Treating Patients with Advanced Colorectal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(12): 1419-1422. DOI: 10.3971/j.issn.1000-8578.2011.12.020
    [8]LI Min, FANG Ming-zhi, QIAN Yin, HUANG Xin, ZHU Xiang. Cetuximab plus Irinotecan in Treatment of Metastatic Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(08): 938-941. DOI: 10.3971/j.issn.1000-8578.2010.08.021
    [9]XU Hua, LIU An-wen, XIE Chun-ying, WU Jian-bing. Clinical Study of TACE with Irinotecan and Lipiodol Combining with Intravenous Chemotherapy of CF/5-Fu in Treatment of Hepatic Metastasis from Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2009, 36(08): 696-698. DOI: 10.3971/j.issn.1000-8578.2009.08.019
    [10]HUANG Yong, QIN Shu-kui, QIAN Jun, SHAO Zhi-jian, L IU Xiu-Feng, L IAO Shi-bin, GONG Xin-lei. Clinical Study of Weekly Irinotecan in Patients with Metastatic Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2005, 32(02): 110-112. DOI: 10.3971/j.issn.1000-8578.1199

Catalog

    Article views (3417) PDF downloads (444) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return